Skip to content
10-K

Annual Report

Amylyx Pharmaceuticals, Inc. AMLX

0000950170-25-031309

← back to feed
Filed
Mar 4, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2024 · Feb 28, 2025 88.6M sh
Shares Diluted FY 2024 · Dec 31, 2023 69.99M sh
Capex FY 2024 · Dec 31, 2023 $1.24M
Operating Cash Flow FY 2024 · Dec 31, 2023 $11.92M
Cash And Equivalents FY 2024 · Dec 31, 2023 $170.2M
Current Liabilities FY 2024 · Dec 31, 2023 $82.04M
Total Liabilities FY 2024 · Dec 31, 2023 $84.02M
Current Assets FY 2024 · Dec 31, 2023 $464.67M
Total Assets FY 2024 · Dec 31, 2023 $517.45M
Eps Diluted FY 2024 · Dec 31, 2023 $0.70
Eps Basic FY 2024 · Dec 31, 2023 $0.73
Sga Expense FY 2024 · Dec 31, 2023 $188.36M
Rd Expense FY 2024 · Dec 31, 2023 $128.19M
Net Income FY 2024 · Dec 31, 2023 $49.27M
Operating Income FY 2024 · Dec 31, 2023 $38.8M
Cost Of Revenue FY 2024 · Dec 31, 2023 $25.44M
Revenue FY 2024 · Dec 31, 2023 $380.79M
Stockholders Equity FY 2024 · Dec 31, 2022 $340.61M